Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA
Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...
News Medical1d
High discontinuation rates of GLP-1 agonists found among patients with obesity
Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
News Medical2d
Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs
Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...
New Truveta study highlights patterns of discontinuation and reinitiation of GLP-1 RA medications
Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...
Benefits Pro24d
State becomes first to add Wegovy-like drugs to essential health benefits package
Zepbound is a brand name for a drug based on tirzepatide, a drug that includes both a GLP-1 agonist and a "gastric inhibitory polypeptide agonist." A GIP agonist promotes weight loss by affecting ...
beckerspayer29d
The first state to cover Ozempic under the ACA
As of Jan. 1, individual ACA plans and small-group plans from employers in the state include coverage for GLP-1s and gastric inhibitory polypeptide drugs, according to the North Dakota Insurance ...